PT003 MDI Dose Confirmation Study

Completed · Phase 2

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

The primary objective of this study is to demonstrate efficacy of PT003 MDI relative to its individual components (PT001 MDI and PT005 MDI) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Key facts

Study ID

NCT01349816

Run by

Pearl Therapeutics, Inc.

People needed

185

Starts

2011-06-01

Expected to finish

2011-11-01

Last updated by the study team

2017-04-27

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Pearl Investigative Site — Rancho Mirage, California, United States
• Pearl Investigative Site — Colorado Springs, Colorado, United States
• Pearl Investigative Site — Waterbury, Connecticut, United States
• Pearl Investigative Site — Clearwater, Florida, United States
• Pearl Investigative Site — Pensacola, Florida, United States
• Pearl Investigative Site — Stockbridge, Georgia, United States
• Pearl Investigative Site — Minneapolis, Minnesota, United States
• Pearl Investigative Site — Brooklyn, New York, United States
• Pearl Investigative Site — Charlotte, North Carolina, United States
• Pearl Investigative Site — Winston-Salem, North Carolina, United States
• Pearl Investigative Site — Cincinnati, Ohio, United States
• Pearl Investigative Site — Medford, Oregon, United States
• Pearl Investigative Site — Spartanburg, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.